CN102065709A - 用于减肥手术患者的营养组合物 - Google Patents
用于减肥手术患者的营养组合物 Download PDFInfo
- Publication number
- CN102065709A CN102065709A CN2009801231301A CN200980123130A CN102065709A CN 102065709 A CN102065709 A CN 102065709A CN 2009801231301 A CN2009801231301 A CN 2009801231301A CN 200980123130 A CN200980123130 A CN 200980123130A CN 102065709 A CN102065709 A CN 102065709A
- Authority
- CN
- China
- Prior art keywords
- composition
- weight
- described composition
- aforementioned
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 238000007681 bariatric surgery Methods 0.000 title claims abstract description 26
- 235000016709 nutrition Nutrition 0.000 title abstract description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000011575 calcium Substances 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 29
- 235000001465 calcium Nutrition 0.000 claims abstract description 29
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 26
- 229910052742 iron Inorganic materials 0.000 claims abstract description 24
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 22
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 21
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 21
- 239000011710 vitamin D Substances 0.000 claims abstract description 21
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 21
- 229940046008 vitamin d Drugs 0.000 claims abstract description 21
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 19
- 239000011785 micronutrient Substances 0.000 claims abstract description 18
- 235000013369 micronutrients Nutrition 0.000 claims abstract description 18
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 16
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 16
- 239000011574 phosphorus Substances 0.000 claims abstract description 16
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 16
- 235000018102 proteins Nutrition 0.000 claims description 29
- 235000014633 carbohydrates Nutrition 0.000 claims description 25
- 235000019197 fats Nutrition 0.000 claims description 23
- 230000002496 gastric effect Effects 0.000 claims description 19
- 230000002641 glycemic effect Effects 0.000 claims description 18
- 230000002980 postoperative effect Effects 0.000 claims description 14
- 229920001202 Inulin Polymers 0.000 claims description 12
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 12
- 229940029339 inulin Drugs 0.000 claims description 12
- 210000002784 stomach Anatomy 0.000 claims description 12
- 208000002720 Malnutrition Diseases 0.000 claims description 11
- 208000008589 Obesity Diseases 0.000 claims description 11
- 208000008279 Dumping Syndrome Diseases 0.000 claims description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 10
- 208000013016 Hypoglycemia Diseases 0.000 claims description 10
- 208000032395 Post gastric surgery syndrome Diseases 0.000 claims description 10
- 210000000988 bone and bone Anatomy 0.000 claims description 10
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 10
- 235000018343 nutrient deficiency Nutrition 0.000 claims description 10
- 230000036186 satiety Effects 0.000 claims description 10
- 235000019627 satiety Nutrition 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 235000019485 Safflower oil Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000000828 canola oil Substances 0.000 claims description 4
- 235000019519 canola oil Nutrition 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 239000003813 safflower oil Substances 0.000 claims description 4
- 235000005713 safflower oil Nutrition 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 208000012696 congenital leptin deficiency Diseases 0.000 claims description 2
- 208000001022 morbid obesity Diseases 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 229940021056 vitamin d3 Drugs 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 36
- 229940088594 vitamin Drugs 0.000 description 13
- 229930003231 vitamin Natural products 0.000 description 13
- 235000013343 vitamin Nutrition 0.000 description 13
- 239000011782 vitamin Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 150000003722 vitamin derivatives Chemical class 0.000 description 12
- 235000014786 phosphorus Nutrition 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000013406 prebiotics Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000001198 duodenum Anatomy 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 210000001630 jejunum Anatomy 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229920002907 Guar gum Polymers 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000000665 guar gum Substances 0.000 description 4
- 235000010417 guar gum Nutrition 0.000 description 4
- 229960002154 guar gum Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 229920001100 Polydextrose Polymers 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229920000617 arabinoxylan Polymers 0.000 description 3
- 230000037180 bone health Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 239000001259 polydextrose Substances 0.000 description 3
- 235000013856 polydextrose Nutrition 0.000 description 3
- 229940035035 polydextrose Drugs 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940029329 intrinsic factor Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 235000020989 red meat Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000037221 weight management Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- AQQWWUIGQFJCMJ-OQQRQXPPSA-N (9z,12z,15z)-octadeca-9,12,15-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O.CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O AQQWWUIGQFJCMJ-OQQRQXPPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 description 1
- 229920000018 Callose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 206010023648 Lactase deficiency Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000021236 calorie-restricted diet Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- -1 iron ion Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pediatric Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种营养组合物,该营养组合物特别适于病态肥胖患者减肥手术前和手术后使用,所述组合物含有20-60重量%的蛋白质源、15-55重量%的碳水化合物、10-20重量%的可溶性膳食纤维、少于10重量%的脂肪以及微量营养素。所述微量营养素含有0.75-3重量%的钙、0.5-1.8重量%的磷、12.5-100mg铁/100g、10-100mcg维生素D/100g以及175-560mcg维生素B12/100g,所述重量百分比基于所述组合物的总干重。
Description
技术领域
本发明涉及营养组合物,该营养组合物特别适于病态肥胖患者减肥手术前和手术后使用。在减肥手术之前的阶段,在采用卡路里受限制的饮食的患者中使用时,该产品有助于减小肝脏尺寸,并且在减肥手术后患者中进一步有助于保持骨骼健康和最佳的营养需要。
所述组合物含有蛋白质、可消化的碳水化合物、膳食纤维、特定的微量营养素,并优选不含脂肪或含非常低量的脂肪。
背景技术
在西方世界,肥胖症的增长速率是影响数百万人的一个主要的健康问题。包括胃旁路术(gastric bypass)的减肥手术程序体现了在病态肥胖的个体中获得显著的体重减轻的一种成功的方式。手术后,估计高达三分之一的患者经受营养缺乏,该营养缺乏不能仅通过正常的饮食来克服。
由文献显而易见的是,营养缺乏在减肥手术前和手术后患者中均常见。这些缺乏具体取决于实施的手术的类型,并且术后缺乏进一步加剧。在美国,最常见的手术为Roux-en-Y胃旁路术(RYGBP),占65.1%;接着是可调节的胃绑扎术(AGB,adjustable gastric band),占24%;垂直绑扎的胃成形术(VBG,vertical banded gastroplasty),占5.4%;以及胆胰绕道术(BPD,bilio-pancreatic diversion),占4.9%[1]。
VBG和AGB为纯粹限制性的,形成30-50mL的胃囊(gastric pouch)。正常的吸收仍是可能的,但是由于食物摄取的总体积大大降低而发生缺乏。RYGBP主要为限制性的,但是也导致一些吸收障碍。胃囊(stomach pouch)缩至20-30mL,并且在手术中十二指肠被完全分流。此外,一短段空肠也可能被分流,导致轻微的脂肪和蛋白质吸收障碍。BPD是具有一些限制的主要的吸收障碍程序[2;3]。
在这组患者中,大的肝脏尺寸妨碍腹腔镜手术。发现急剧的术前重量减轻方案(4-6周)会显著减小肝脏尺寸。由于目前可用的重量减轻产品仅含最高达到RDA水平的微量营养素,因此对于没有额外的多种维生素补充的患者,该减重产品不能被设计用于解决这组患者的特定的微量营养素的需求。为了满足微量营养素的RDA,除了每日数次服用多种维生素以外,还可能需要消耗高达5份含有体重管理配方(weight management formula)的蛋白质。每天数次补充的需要能导致顺应性(compliance)随着时间而降低,因而导致临床缺乏。
蛋白质营养不良为减肥手术患者真正的风险。许多患者在快速重量减轻的早期阶段需要蛋白质补充,以防止肌肉质量的过度损失。用于减肥手术前和手术后的患者,特别设计以满足或超过微量营养素需要的,含蛋白质、低卡路里的产品的优点在于,患者能学会将健康饮食与产品使用相结合,即使是在手术程序进行之前,也不会完全依赖膳食替代品。
发明内容
因此,本发明的目的为制备一种满足胃旁路术患者特定的营养需求的均衡的营养产品。为此,本发明提供了一种组合物,该组合物含有20-60重量%的蛋白质源、15-55重量%的碳水化合物、10-20重量%的可溶性膳食纤维、少于10重量%的脂肪以及微量营养素,其中,所述微量营养素含有,
0.75-3重量%的钙,
0.5-1.8重量%的磷,
12.5-100mg铁/100g,
10-100mcg维生素D/100g,以及
175-560mcg维生素B12/100g,
所述重量百分比基于所述组合物的总干重。
单位“mcg”表示微克。
根据本发明的组合物特别设计用于肥胖的胃旁路术患者,当术前使用时,用于诱导肝脏尺寸减小,预防和/或治疗骨钙流失(bone calcium depletion)和骨质缺乏(osteopenia),预防和治疗术后营养缺乏,改善GI功能或肠健康,诱导术前和术后重量减轻,诱导饱腹感,预防倾倒综合症或保持血糖控制(glycaemic control)。因此,该产品设计用于实施减肥手术前和手术后的患者,可看作是饮食处方计划(prescribed diet plan)的一部分。
根据本发明的组合物含有蛋白质和特别设计的维生素与矿物质的共混物。该产品将满足或超过所有维生素、微量元素、镁和磷的RDA,并且卡路里和体积低。
本发明的优选的特征如以下(i)-(vi)所列。
(i)蛋白质源为低乳糖或不含乳糖的蛋白质源(优选基于乳清,还更优选为水解的形式),存在于所述组合物中的量为20-60g/100g所述组合物(即,20-60重量%),更优选为20-40g/100g所述组合物(即,20-40重量%)。
(ii)碳水化合物(其存在的量为15-55重量%)优选为低血糖碳水化合物(glycemic carbohydrate),例如选自果糖、半乳糖、异麦芽酮糖和可缓慢消化的淀粉。
(iii)可溶性膳食纤维,存在于所述组合物中的量为10-20重量%,优选为菊粉和/或果寡糖(oligo fructose)。
(iv)存在于所述组合物中的脂肪为杂红花油(hybrid safflower oil)、芥花籽油(canola oil)和椰子油(coconut oil)的共混物,该共混物提供最佳比例的亚油酸(linoleic)与α-亚麻酸(α-linolenic acid)。
(v)铁(存在的量为12.5-100mg铁/100g组合物)优选被脂肪涂布。
(vi)钙与磷的比例(即,Ca∶P比例)为1.4。
根据本发明的优选的组合物包括(i)-(vi)的所有特征。
具体实施方式
根据本发明的产品预期用于,当术前使用时,支持肝脏尺寸减小,手术后保持骨骼健康的营养生物标志(PTH;甲状旁腺激素),(n.b.实施胃旁路术后患者中PTH浓度提高,长时间后能导致骨钙流失,从而导致骨质缺乏)。该产品通过帮助矿物质吸收(通过益生元夹杂(prebiotic inclusion)),改善GI功能/肠健康以及支持术前和术后重量减轻,解决了术前和术后营养缺乏,这是由于该产品仅贡献低卡路里饮食的总能量需求的27%(推荐的卡路里摄取为约1200kcal/天)。该产品具有饱腹感诱导效应(satiety inducing effect),低升糖指数,并且避免倾倒综合征。
根据本发明的组合物含有20-60重量%的蛋白质源、15-55重量%的低血糖碳水化合物、10-20重量%的可溶性膳食纤维、少于10重量%的脂肪以及微量营养素,其中,所述微量营养素含有,每100干重产品:12.5-100mg铁、175-560mcg维生素B12、0.75-3g钙、10-100mcg维生素D以及0.5-1.8g磷,优选Ca∶P比例为1.4,其中,所述重量%基于所述组合物的总干重,并且“mcg”代表微克。磷的量可以是0.5-1.5重量%。可选择地或除此以外,维生素B12的量可以是175-500mcg。
蛋白质源:
蛋白质的水平处于20-60g/100g粉末之间(即,20-60重量%),并且预期共计提供20-40g蛋白质/天,其余的由饮食提供。对于减肥患者,日需要量为60-70g/天。由于术后经历的乳糖不耐受,优选低乳糖或不含乳糖的蛋白质源。
在一种优选的实施方式中,蛋白质为水解产物形式。蛋白质水解产物(肽的来源)广泛用于在肠内消化或吸收全部蛋白质有困难的情况。通过载体介导的输送系统,小肽在穿过肠壁的整个过程中被吸收。一旦被吸收,小肽被肽酶水解。得到的游离的氨基酸接着进入门脉循环(portal circulation)。因此,含有蛋白质水解产物将提供蛋白质来源容易且容易被吸收的潜在的益处。但是,如果需要改善味道,则整个蛋白质(优选基于乳清的,由于乳清比酪蛋白更容易消化)可以用作蛋白质源的部分或全部。蛋白质还具有轻微的饱腹感诱导效应。因此,在所述组合物中含有大量的蛋白质的另一个潜在的益处是饱腹感诱导效应。
碳水化合物和纤维:
由于根据本发明的产品设计为具有低卡路里密度,所用碳水化合物处于15-55g/100g粉末之间,并且预期提供最多55g碳水化合物/天。GBP患者的一个重要的考虑是当糖快速移动通过胃和肠时发生倾倒综合征的可能性。倾倒综合征引起恶心、虚弱、出汗、昏眩,并且可能在进食后立即出现腹泻。优选该产品具有低的总升糖指数(overall low glycemic index),以确保将葡萄糖缓慢地释放至血流中。
消耗低GI产品对于肥胖的糖尿病患者的总血糖控制具有积极效果,并且结合重量减轻将导致患者减少或完全停止他们的糖尿病药物治疗。优选总升糖指数为中等(36-50),并且理想地,为低GI(<36)。因此,根据本发明的组合物特别适于改善减肥手术前和手术后的肥胖的糖尿病患者的血糖控制,同时能预防或恢复与营养缺乏相关的重量减轻。
在另一种优选的实施方式中,所述组合物含有低升糖指数的碳水化合物,即,升糖指数(GI)低于50的碳水化合物。这些碳水化合物优选含有果糖(19)、半乳糖(23)、异麦芽酮糖(33)和/或可缓慢消化的淀粉,例如玉米淀粉。或者,通过抑制消化酶(α-淀粉酶)能降低所述组合物的升糖指数,消化酶引起复合碳水化合物(complex carbohydrates)的消化。减慢该消化过程降低了含有麦芽糊精和/或淀粉的食物的升糖指数(GI)。使用这些低GI碳水化合物将导致减肥手术前和手术后改善的血糖控制。
膳食纤维的一个关键的益处是它们能提高矿物质(特别是钙)的吸收。本发明人发现该益处在肥胖的个体和经过GBP手术后的患者中是尤其理想的,肥胖的个体在晚年具有更高的患有骨关节炎、骨质疏松和骨骼脆弱的风险,经过GBP手术之后的患者由于维生素D和钙的缺乏而可能具有骨脱矿质(bone demineralization)的风险。
可以将根据本发明的粉末状组合物稀释,以提供饮品或甜点(mousse)。对于经过胃旁路术手术之后的患者,该产品所建议的一种益处为包括诱导饱腹感感觉的非营养性成分(non-nutritive ingredients),因此防止患者消耗比所需更大量的食物。许多可能的组分被报道在该领域具有潜在的益处,例如瓜耳胶(guar gum)、果胶(pectin)或粘液(mucilages),通过它们的形成凝胶的作用,延迟胃排空。然而,传统的增稠成分(例如上述这些物质)对于小体积产品(例如本发明的产品)不理想,本发明人发现,使用可溶性膳食纤维(例如益生元)被认为代表了最有希望的选择。优选体积尽可能小,但是至少小于150mL,因为这种小体积最容易被术后患者接受。
用于本发明的膳食纤维通常不会在人小肠中消化和吸收,而是优选在大肠中完全或部分发酵。本发明的组合物优选含有至少一种能刺激肠中的双歧杆菌(bifodobacteria)生长的膳食纤维,该膳食纤维选自由半乳糖寡糖(包括反式半乳糖寡糖)、菊粉、果寡糖、木寡糖、低聚异麦芽酮糖(palatinoseoligosaccharide)、抗性淀粉、乳果糖、低聚乳果糖(lactosucrose)、甘露寡糖(mannanoligosaccharides)、低聚异麦芽糖、低聚麦芽糖、葡甘露聚糖、阿拉伯半乳聚糖、大豆寡糖、龙胆低聚糖(gentiooligosaccharide)、果胶(pectin)、果胶酸盐、硫酸软骨素(chondroitine)、透明质酸、肝素(heparine)、类肝素(heparane)、细菌性碳水化合物(bacterial carbohydrates)、唾液聚糖(sialoglycans)、岩藻寡糖(fucooligosaccharides)、黄原胶、聚葡萄糖(PDX)、半乳甘露聚糖组成的组中,优选瓜耳胶(guar gum)、阿糖基木聚糖,优选根据美国专利5,560,914的MGN-3米糠阿糖基木聚糖(Rice Bran Arabinoxylan)、木聚糖(xyloglycan)、愈创葡聚糖,和/或它们的降解产物。所有这些在肠系统中具有有益的益生元和双岐效应(bifidogenic effects)。PDX是由无规交联的葡萄糖和山梨糖醇合成的不可消化的碳水化合物。
本发明人发现,由于果寡糖(fructooligosaccharides)和菊粉这些成分在整个结肠中发酵,果寡糖和菊粉的组合导致持续较长的饱腹感感觉。当患者适应并能摄取较大量的食物可能导致不希望的体重增加时,这些膳食纤维具有较大的长期相关性(relevance longer term)。
除了在饱腹感诱导中的作用以外,据确定地报导,膳食纤维通过增加身体对侵入的病原体的天然抗性,对于具有胃肠健康刺激的良好的结肠微生物区系(microflora)的开发是重要的。因此,根据本发明的含有膳食纤维的组合物的一个优选的应用是,特别适用于刺激肥胖的减肥手术患者对侵入的病原体的天然抗性。
增加的血液胆固醇是肥胖的减肥手术患者的主要问题。这些患者的部分饮食治疗涉及血液胆固醇水平的降低。含有膳食纤维的主要益处在于膳食纤维对降低血液胆固醇水平的效果,这一点已通过一些研究得到证实[4;5]。
根据本发明的一种优选的实施方式含有OraftiTM Synergy 1益生元,该益生元为富含果寡糖的菊粉,含有短链和长链寡糖的组合。两种组分的组合比起单个的组分在生理学上更有效。虽然对于膳食纤维的摄取没有容许摄取的上限标准(UL),但是在摄取超过15-18g菊粉/天时,可以预期痛苦(例如腹泻、气胀(flatulence)、发胀(bloating)和痉挛)。因此,该产品为已进行减肥手术的该组患者而设计,并且每日摄取受限,优选摄入处于5-25g/天之间水平的OraftiTM Synergy 1。由于在以前的研究中在具有较低的GI状况(例如溃疡性结肠炎或结肠癌)的患者中被报道,这些水平是这组患者能耐受的。
脂肪:
在该组患者中不需要含有额外的脂肪来源。在这个组中不鼓励含有脂肪,这是由于脂肪能显著提高饮食的卡路里含量。因此,含有脂肪还将提高建议补充的卡路里含量。目标是导致非常低的卡路里补充,其中卡路里水平处于0-10g/100g之间,优选处于0-5g/100g粉末之间。有时需要脂肪来优化产品的味道和可接受性。如果使用脂肪来源,优选的共混物含有杂红花油、芥花籽油和椰子油。这种共混物将提供足够量的α-亚麻酸(ALA),α-亚麻酸随后通过肝脏转化为二十碳五烯酸(EPA)。优选提供最佳比例的亚油酸(LA)与α-亚麻酸(ALA),其中,所述提供的LA的水平为1.8g/天,优选处于1.3-2.7g/天之间。优选提供的ALA的水平为0.45g/天,优选处于0.27-0.67g/天之间。优选这些数值满足LA与ALA的比例为4∶1至10∶1。
或者,可使用含有二十碳五烯酸(EPA)的脂肪共混物,其中,至少提供0.1g EPA/100g干重,优选提供处于0.1-0.5g EPA/100g干重之间。
微量营养素:
所述组合物含有一定水平的微量营养素铁、钙、磷、维生素D、维生素E和维生素B12,以满足实施减肥手术之后的患者特定的需要。以下详述这些的基本原理。为满足高达150%的美国RDA水平,将提供其余的维生素、微量元素和镁,这是由于建议所有患者进行术前多种维生素的补充(含有增加的铁和其它微量营养素)作为预防性测量,而与他们是否确定缺乏无关。电解质钠、钾和氯的含量以固有的水平存在于所用成分中。
铁:
在实施减肥手术之后,铁缺乏似乎非常常见。已报道缺乏的发生率在14-52%范围内。为了通过饮食吸收非血红素铁,需要胃酸将铁离子还原为亚铁态。由于肥胖手术,胃酸的量大大减少,从而限制从食物中吸收铁。铁还在十二指肠(被完全分流)和邻近的空肠(其中的一些在手术中被分流)中被吸收。在经期的妇女中,该缺乏进一步加剧。根据本发明的组合物含有12.5-100mg铁/100g干重产品,优选处于12.5-75mg/100g之间,预期提供日剂量为12.5-60mg。在一种优选的实施方式中,铁的建议含量仅低于美国上限45mg/天。在另一种优选的实施方式中,使用被脂肪涂布的铁(fat coatediron)。这样做的优点在于显著改善所述组合物的味道。
维生素B12:
在正常的、健康的个体中,需要胃酸和胃蛋白酶酸(peptic acid)从食物中释放维生素B12。在十二指肠中,维生素接着与内源因子(intrinsic factor)结合,维生素随后在末端回肠中被吸收。减肥手术后,由于分泌酸的细胞大多数位于胃的底部,而胃的底部被分流,胃酸几乎不存在,使得对于患者来说难以有效地释放在食物中结合的维生素B12。这种维生素的有效来源主要是红肉和乳制品,而红肉和乳制品由于不耐受可能排除于或者受限制于这组患者的饮食中,使得需要甚至更难以满足。在文献中描述了时常存在缺少可能导致延迟病症诊断的情况的症状,如果缺乏保持长时间段,该情况导致不可逆的神经病学损伤。
根据本发明的组合物含有维生素B12,其量为175-560mcg/100g(更优选为175-500mcg/100g),以匹配150mcg的日最低水平。由于患者存在维生素B12吸收的问题,优选使用较高水平的这种维生素,以便使维生素的可用性最大化,随着摄取的增加,总吸收也提高。因此,一种优选的实施方式含有维生素B12的量为250-500mcg/100g产品,还更优选275-500mcg/100g产品,导致日剂量至少为250mcg。
钙、维生素D和磷:
据报道,术前钙和维生素D的水平不正常。假定这可能是由于运动减少,日照减少以及身体脂肪的储存提高,使得生物利用度降低。
在这组患者中可预料钙缺乏,这是由于食物中的钙大多数在十二指肠和邻近的空肠中被吸收,在RYGBP中,通过维生素D介导的非活性可饱和的过程将十二指肠和邻近的空肠分流。还需要胃酸将食物中的钙转化为可溶形式以利于吸收。由于不耐受引起的乳制品的摄取降低,继发乳糖酶缺乏或以前隐藏的不耐受也将导致术后钙摄取降低。本发明人发现,所有患者应补充至少等于或超过RDA的水平。因此,一种优选的实施方式含有处于1200-1500mg之间的钙作为日剂量。
根据本发明的产品中的钙的优选的水平为至少1000mg/100g(即,1重量%),提供至少1000mg钙/天。还更优选所述组合物含有处于1200-3000mg之间的钙/100g,提供至少1500mg/天。不束缚于理论,本发明人预期这些较高水平的钙将容许钙在这组患者中的最佳吸收。为了提高生物利用度,将使用柠檬酸盐或葡糖酸盐形式的钙。
一些回顾性研究已显示实施胃旁路术手术之后维生素D的缺乏。通过维生素D依赖机理,钙还能在小肠的碱性环境中被吸收。每100g产品,维生素D的范围处于10-100mcg之间,优选处于10-30mcg之间(更优选10-20mcg),使得日摄取至少为10mcg。在一种优选的实施方式中,由于维生素D3形式比维生素D2在增加循环中的维生素D激素水平上更有效,因此使用维生素D3。这些较高水平有助于优化钙吸收。
磷的建议水平是500-1800mg/100g(即,0.5-1.8重量%),更优选500-1500mg/100g(即,0.5-1.5重量%)。这些水平远低于美国上限4000mg。为了使骨骼健康最大化,根据RDA,保持Ca∶P比例为1.4是谨慎的。
维生素C和维生素E:
优选的维生素C的水平处于50-2000mg/100g产品之间。19-50岁的男性比女性需要稍高的维生素C,其RDA为90mg/天。任何过量的维生素容易被身体排泄,并且维生素C的上限是2000mg/天。
优选的维生素E的水平处于20-1000mg维生素E等价物/100g产品之间。这样将提供总的日摄取至少为40mg。美国RDA处于15-19mg/天范围内,而美国上限为1000mg/天。在不存在确定的RYGBP之后维生素E缺乏的证据时,如前所述,目标是提供至少满足推荐的摄取的水平,并且还用于减小氧化应激(oxidative stress)。
由于在该产品中提高铁摄取量,因此掺入这些提高水平的维生素C和维生素E。目标是提供至少满足推荐的摄取的水平,并且还用于减小氧化应激。已知维生素C有助于吸收非血红素铁。Cook和Monsen[9]发现,铁吸收的增加与加入的维生素C的量正好成比例。ICMR Bulletin report(2000)推荐,为了减小人的氧化应激,每日给药治疗剂量的铁必须伴随着补充抗坏血酸与维生素E的组合。
能量密度:
总卡路里保持最低。优选每种组合物含有少于500kcal/100g,还更优选处于200-400kcal/100g之间。
包装
粉末制剂
本发明的组合物可以是以粉末形式供应给患者。该粉末可以随后与水一起重新组成。可以加入足够的水以制作低体积饮品,或者可以加入较少的水以得到甜品样稠度(mousse like consistency)。
举例说明,粉末可以以含有约45.3g粉末的(一剂)小袋形式供应。可以使用80mL水来重新组成为低体积饮品。可以加入较少的水(20-30mL)以得到甜品样稠度。可以设计粉末,使得该粉末能组成“布丁”或“饮品”。
液体制剂
或者,可以由制造商重新组成粉末,并且以“易饮用”制剂的形式供应给患者。由于减肥手术患者的胃体积小,必要的是保持产品的体积小。优选单剂量的体积应不超过150mL,更优选不大于100mL,还更优选小于50mL。本发明人预期如果体积超过最大体积150mL,则减肥手术患者将不能遵守为获得产品声称的效果所需的产品摄取。
组合物的应用
所述组合物可以用于改善减肥手术患者的一些症状。所述症状的实例为肥胖、骨质缺乏、倾倒综合征和营养缺乏。
根据本发明的组合物能优选用于达到以下目的的方法中:
a.当术前使用时,诱导肝脏尺寸减小,
b.预防和治疗术后营养缺乏,
c.预防倾倒综合征,
d.诱导术前和术后重量减轻,
在肥胖的胃旁路患者中,其中,所述方法包括给药组合物,该组合物含有20-60重量%的蛋白质源、15-55重量%的碳水化合物、10-20重量%的可溶性膳食纤维、少于10重量%的脂肪以及微量营养素,其中,所述微量营养素含有12.5-100mg铁/100g、0.175-0.560mcg维生素B12、0.75-3重量%的钙、0.000010-0.000100重量%(10-100mcg/100g)的维生素D以及0.5-1.8重量%的磷,其中,所述重量百分比基于所述组合物的总干重。磷的量可以是0.5-1.5重量%。可选择地或除此以外,维生素B12的量可以是175-500mcg。
骨质缺乏是指骨矿物质密度(BMD,bone mineral density)低于正常的峰值BMD,但是不足以低至可分类为骨质疏松。骨矿物质密度是骨骼中矿物质水平的量度,骨矿物质密度表明骨骼中矿物质如何致密和强壮。如果与正常的峰值BMD相比BMD低,则认为骨质缺乏。患有“骨质缺乏”意味着随着时间的流逝,存在可以发展成为与正常值相比BMD非常低的较大的风险,即,所称的骨质疏松。肥胖并进行减肥手术的患者发展成为骨质缺乏和骨质疏松的风险提高。由于根据本发明的组合物含有相对较高量的钙、磷和维生素D,因此根据本发明的组合物特别适于预防和/或治疗这些患者的骨质缺乏和骨质疏松。
倾倒综合征在某些类型的胃手术的患者中最常见,例如容许胃快速排空的胃切除术或胃旁路术。当小肠的较低端(空肠)被来自胃的未经消化的食物快速填充时,发生胃倾倒综合征或快速胃排空。“早期”倾倒开始于就餐过程中或者在刚用餐后。早期倾倒的症状包括恶心、呕吐、发胀、痉挛、腹泻、眩晕和疲劳。“晚期”倾倒发生在餐后1-3小时。晚期倾倒的症状包括虚弱、出汗以及眩晕。许多人出现两种类型的倾倒。此外,患有该综合征的人们经常经受低血糖或血糖过低(hypoglycemia),因为食物的快速“倾倒”引发胰脏将过量的胰岛素释放至血流中。这种类型的血糖过低称为“滋养性血糖过低(alimentary hypoglycemia)”。由于产品中的高蛋白质水平和纤维将降低胃排空速率,并且低血糖碳水化合物(glycemic carbohydrates)将减小葡萄糖水平的升高,即,血液中的葡萄糖吸收速率,因此根据本发明的组合物特别适于治疗和/或预防倾倒综合征。
肥胖为进行减肥手术的主要原因。在开始手术之前,可能需要诱导重量减轻,并且在成功的手术之后,可能需要诱导饱腹感以及提供足够的必需维生素和矿物质。在一种优选的实施方式中,根据本发明的组合物能用于治疗减肥手术患者的与重量减轻相关的症状。
实施例1
该实施例描述了优选的用于治疗减肥手术患者的粉末形式的营养组合物。
1乳糖含量约为0.25%
2MD∶MS约为3.3∶1
3例如Orafti(约50%短链果寡糖和50%长链菊粉)
如所述的,所述组合物的总重量为90.6g。这代表了每天给药患者的量。将该产品包装为两个小袋,每个小袋含有45.3g制剂。将每个小袋与水混合,得到体积为125-135mL的液体产品。患者每天服用两个该液体产品。
参考文献
1.Xanthakos SA,Inge TH.Nutritional consequences of bariatric surgery.Curr Opin Clin Nutr Metab Care 2006;9:489-96.
2.Malinowski SS.Nutritional and metabolic complications of bariatric surgery.Am J Med Sci 2006;331:219-25.
3.Parkes E.Nutritional management of patients after bariatric surgery.Am J Med Sci 2006;331:207-13.
4.Jackson KG,Taylor GR,Clohessy AM,Williams CM.The effect of the daily intake of inulin on fasting lipid,insulin and glucose concentrations in middle-aged men and women.Br J Nutr 1999;82:23-30.
5.Brighenti F,Casiraghi MC,Canzi E,Ferrari A.Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers.Eur J Clin Nutr 1999;53:726-33.
6.Langlands SJ,Hopkins MJ,Coleman N,Cummings JH.Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel.Gut 2004;53:1610-6.
7.Davidson MH,Maki KC.Effects of dietary inulin on serum lipids.J Nutr 1999;129:1474S-7S.
8.Pedersen A,Sandstrom B,Van Amelsvoort JM.The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females.Br J Nutr 1997;78:215-22.
9.Cook JD,Monsen ER.Vitamin C,the common cold,and iron absorption.Am J Clin Nutr 1977;30:235-41.
Claims (24)
1.一种组合物,该组合物含有20-60重量%的蛋白质源、15-55重量%的碳水化合物、10-20重量%的可溶性膳食纤维、少于10重量%的脂肪以及微量营养素,其中,所述微量营养素含有
0.75-3重量%的钙,
0.5-1.8重量%的磷,
12.5-100mg铁/100g,
10-100mcg维生素D/100g,以及
175-560mcg维生素B12/100g,
所述重量百分比基于所述组合物的总干重。
2.根据权利要求1所述的组合物,其中,所述组合物含有0.5-1.5重量%的磷。
3.根据权利要求1所述的组合物,其中,所述组合物含有175-560mcg维生素B12/100g。
4.根据权利要求1所述的组合物,其中,所述组合物含有0.5-1.5重量%的磷和175-500mcg维生素B12/100g。
5.根据权利要求1-4中的任意一项所述的组合物,其中,所述碳水化合物的升糖指数低于50。
6.根据权利要求5所述的组合物,其中,所述碳水化合物含有选自由果糖、半乳糖、异麦芽酮糖和可缓慢消化的淀粉组成的低血糖碳水化合物组中的至少一种。
7.根据权利要求1-6中的任意一项所述的组合物,其中,所述蛋白质源为低乳糖或不含乳糖的蛋白质源。
8.根据权利要求7所述的组合物,其中,所述组合物含有20-60重量%的所述低乳糖或不含乳糖的蛋白质源。
9.根据权利要求8所述的组合物,其中,所述组合物含有20-40重量%的所述低乳糖或不含乳糖的蛋白质源。
10.根据前述权利要求中的任意一项所述的组合物,其中,所述可溶性膳食纤维至少含有菊粉和/或果寡糖。
11.根据前述权利要求中的任意一项所述的组合物,其中,所述脂肪含有杂红花油、芥花籽油和椰子油的混合物。
12.根据前述权利要求中的任意一项所述的组合物,其中,所述维生素D的量为10-30mcg/100g所述组合物的干重。
13.根据权利要求12所述的组合物,其中,所述维生素D的量为10-20mcg/100g所述组合物的干重。
14.根据前述权利要求中的任意一项所述的组合物,其中,所述维生素D基本上由维生素D3组成。
15.根据前述权利要求中的任意一项所述的组合物,其中,所述组合物含有12.5-75mg铁/100g。
16.根据前述权利要求中的任意一项所述的组合物,其中,所述铁为被脂肪涂布的铁。
17.根据前述权利要求中的任意一项所述的组合物,其中,所述组合物含有250-500mcg维生素B12/100g。
18.根据前述权利要求中的任意一项所述的组合物,其中,所述组合物含有1.2-3重量%的钙。
19.根据前述权利要求中的任意一项所述的组合物,其中,钙与磷的比例Ca∶P为1.4。
20.根据前述权利要求中的任意一项所述的组合物,其中,该组合物用于在肥胖的胃旁路术患者中进行
a.当术前使用时,诱导肝脏尺寸减小,
b.预防和/或治疗骨钙流失和骨质缺乏,
c.预防和治疗术后营养缺乏,
d.改善升糖指数功能或肠健康,
e.诱导术前和术后重量减轻,
f.诱导饱腹感,或者
g.预防倾倒综合征,
h.保持血糖控制。
21.根据权利要求1-19中的任意一项所述的组合物,其中,所述组合物用于减肥手术患者术前和术后治疗。
22.根据权利要求21所述的组合物,其中,所述手术选自Roux-en-Y胃旁路术、可调节的胃绑扎术、垂直绑扎的胃成形术以及胆胰绕道术。
23.权利要求1-19中的任意一项所述的组合物在制备用于治疗胃旁路手术后肥胖患者的医学营养素中的应用。
24.权利要求1-19中的任意一项所述的组合物在制备用于治疗胃旁路手术前和手术后的病态肥胖患者营养缺乏的医学营养素中的应用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2008/004943 | 2008-06-19 | ||
EP2008004943 | 2008-06-19 | ||
PCT/EP2009/004469 WO2009153065A1 (en) | 2008-06-19 | 2009-06-19 | Nutritional composition for bariatric surgery patients |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102065709A true CN102065709A (zh) | 2011-05-18 |
Family
ID=40351852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801231301A Pending CN102065709A (zh) | 2008-06-19 | 2009-06-19 | 用于减肥手术患者的营养组合物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110081400A1 (zh) |
CN (1) | CN102065709A (zh) |
BR (1) | BRPI0914793B1 (zh) |
WO (1) | WO2009153065A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102429149A (zh) * | 2011-11-17 | 2012-05-02 | 吉林大学 | 一种含咸蛋清蛋白多肽的肠内营养制剂及其制备方法 |
CN107105753A (zh) * | 2014-08-04 | 2017-08-29 | 克里斯托弗·布赖恩·伦丁 | 食物制品 |
CN108244625A (zh) * | 2018-01-11 | 2018-07-06 | 广州拜扬生物科技有限公司 | 一种减肥手术后的营养代餐食品 |
CN111513322A (zh) * | 2020-05-29 | 2020-08-11 | 成都尚医信息科技有限公司 | 一种用于减重术后病人的流质食品及其制备方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2996419B1 (fr) * | 2012-10-09 | 2015-05-29 | Internat Nutrition Res Company | Produit dietetique destine a etre administre aux personnes obeses recemment operees en chirurgie bariatrique |
WO2014071176A1 (en) * | 2012-11-02 | 2014-05-08 | Disilvestro Robert | Nutritional supplements including meal replacements and related methods |
WO2016164990A1 (pt) * | 2015-04-13 | 2016-10-20 | Masselli Deluz | Kit alimentação e nutrição para perda de peso sustentada pré/pós cirurgia bariátrica |
CA2990230A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
US11272728B2 (en) * | 2015-11-30 | 2022-03-15 | Fresenius Kabi Deutschland Gmbh | High protein enteral tube feed for ICU patients |
EP3184111A1 (en) * | 2015-12-21 | 2017-06-28 | Abbott Laboratories | Compositions comprising carbohydrates |
NL2019348B3 (en) * | 2017-07-26 | 2019-09-05 | Ams Advanced Medical Supplements B V | Pharmaceutical composition for use in the treatment or prevention of vitamin deficiency and mineral deficiency in patients who have been subjected to gastric sleeve surgery |
US11213059B2 (en) * | 2017-12-22 | 2022-01-04 | Mantra Pharma | Nutritional formulations and kits for bariatric individuals |
JP2020103244A (ja) * | 2018-12-28 | 2020-07-09 | 株式会社東洋新薬 | 飲食用組成物 |
CN109892555A (zh) * | 2019-02-28 | 2019-06-18 | 珠海市优尼赞经贸有限公司 | 一种阻碍脂肪合成加速排油减脂的减肥食品及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4877627A (en) * | 1986-08-19 | 1989-10-31 | Nutrilite Products, Inc. | Balanced fiber composition |
GB9808579D0 (en) | 1998-04-22 | 1998-06-24 | Novartis Nutrition Ag | Improvements in or relating to organic compounds |
AU9433698A (en) * | 1998-10-09 | 2000-05-01 | Sanacare Aps | Diet food |
GB0100273D0 (en) * | 2001-01-08 | 2001-02-14 | Nestle Sa | Nutritional composition for a bone condition |
US6808736B2 (en) * | 2001-06-07 | 2004-10-26 | Nestec S.A. | Soy hydrolysate based nutritional formulations |
US20040005368A1 (en) * | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
SE526943C2 (sv) | 2002-08-26 | 2005-11-22 | Indevex Ab | Födoämneskompositionsprodukt |
US7744930B2 (en) * | 2002-11-22 | 2010-06-29 | Shaklee Corporation | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass |
US20080107715A1 (en) * | 2006-11-03 | 2008-05-08 | Miller Eric C | Pharmaceutical containing food compositions and uses thereof |
-
2009
- 2009-06-19 WO PCT/EP2009/004469 patent/WO2009153065A1/en active Application Filing
- 2009-06-19 CN CN2009801231301A patent/CN102065709A/zh active Pending
- 2009-06-19 BR BRPI0914793-4 patent/BRPI0914793B1/pt active IP Right Grant
-
2010
- 2010-12-13 US US12/966,267 patent/US20110081400A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102429149A (zh) * | 2011-11-17 | 2012-05-02 | 吉林大学 | 一种含咸蛋清蛋白多肽的肠内营养制剂及其制备方法 |
CN107105753A (zh) * | 2014-08-04 | 2017-08-29 | 克里斯托弗·布赖恩·伦丁 | 食物制品 |
CN108244625A (zh) * | 2018-01-11 | 2018-07-06 | 广州拜扬生物科技有限公司 | 一种减肥手术后的营养代餐食品 |
CN111513322A (zh) * | 2020-05-29 | 2020-08-11 | 成都尚医信息科技有限公司 | 一种用于减重术后病人的流质食品及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0914793B1 (pt) | 2019-12-10 |
US20110081400A1 (en) | 2011-04-07 |
WO2009153065A1 (en) | 2009-12-23 |
BRPI0914793A2 (pt) | 2015-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102065709A (zh) | 用于减肥手术患者的营养组合物 | |
CN102131405B (zh) | 用于减肥手术患者的液体营养组合物 | |
AU2006301389B2 (en) | Nutrition for obese patients | |
CA2234398C (en) | Composition and method for providing nutrition to diabetics | |
RU2420210C2 (ru) | Высококалорийная питательная добавка | |
US6884445B2 (en) | Matrix-forming composition containing pectin | |
CN106690290A (zh) | 一种高膳食纤维全营养特殊医学用途配方食品及其制备方法 | |
PT1588629E (pt) | Composição que contém pectina para formar uma matriz | |
CA2532311C (en) | High fibre high calorie liquid or powdered nutritional composition | |
IL178049A (en) | Dietary supplement for the treatment and prevention of digestive system and digestive system-related disorders comprising a lipid supplement, a soluble fiber and at least one amino acid | |
WO2014204382A1 (en) | Administration of a food composition product | |
EP1410722A1 (en) | Weight loss kit and method for losing weight | |
WO2015009225A1 (en) | Food composition product | |
KR100787554B1 (ko) | 혈중 저분자량질소함유화합물의 농도 저감용 식품 | |
EP2285240B1 (en) | Nutritional composition for bariatric surgery patients | |
Russell et al. | Is there a role for specialized enteral nutrition in the intensive care unit? | |
WO2014150351A1 (en) | Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women | |
EP2299850A2 (en) | Liquid nutritional composition for bariatric surgery patients | |
MXPA98005035A (en) | Composition and method for providing nutrition to diabeti | |
Rogula et al. | Laparoscopic Roux-en-Y gastric bypass: Postoperative management and nutritional evaluation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110518 |